Can frequent CRP checks prevent relapses in giant cell arteritis?

NCT ID NCT07720804

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This pilot study is investigating how quickly C-reactive protein (CRP), a key marker of inflammation, drops after starting steroid treatment in people newly diagnosed with giant cell arteritis. By measuring CRP levels daily, then weekly and monthly for up to a year, researchers hope to understand how CRP changes relate to symptoms and whether early normalization could guide treatment adjustments to avoid complications or relapses. The study involves 40 adults hospitalized with a new diagnosis of giant cell arteritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
blood tests to measure C-reactive protein (CRP) levels
What this could lead to
If successful, this could help doctors personalize steroid dosing for giant cell arteritis, potentially reducing complications and relapses.
What could go wrong
This is a small pilot study with only 40 participants, so findings may not apply to all patients. It is observational and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.